Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs

Introduction: The emergence of several therapeutic options in multiple sclerosis (MS), which significantly modify the immune system functioning, has led to the need for the consideration of additional factors, such as risk of infections, in the decision-making process. The aim of these consensus recommendations was to discuss and perform a practical guide to Latin American neurologists on the risk of infections at diagnosis, follow-up and prior to initiation of DMDs.Methods: A panel of Latin American neurologists, experts in demyelinating diseases and dedicated to manage-ment and care of MS patients, gathered during 2021 and 2022 to make consensus recommendations on the risk of infections in PwMS treated with DMDs in Latin America. The RAND/UCLA methodology was developed to synthesize the scientific evidence and expert opinions on health care topics and was used for reaching a formal agreement.Results: Recommendations were established based on relevant published evidence and expert opinion, focusing on: 1-baseline infection disease and vaccination status; 2-opportunistic infections; 3-progressive multifocal leukoencephalopathy; 4-genitourinary system infections; 5-respiratory tract infections; 6-digestive system infections, 7-others local infections and 8-COVID-19.Conclusion: The recommendations of this consensus seek to optimize the care, management and treatment of PwMS in Latin America. The standardized evidence-based care of pwMS infections will allow better outcomes.